News
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
Terrana is aiming to have commercially available products in the next few years, pending regulatory approval, that can be applied as sprayables or seed treatments. And the company says its RNA-based ...
3h
Zacks Investment Research on MSNCompany News for Jul 1, 2025Meta Platforms Inc.’s (META) shares rose 0.6% after the company recruited several key AI researchers for its newly developed superintelligence labs. Shares of Moderna Inc. (MRNA) gained 1.6% after its ...
Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...
Some of the market’s most expensive stocks are also its weakest earners, bleeding losses despite lofty valuations. For ...
CLEBURNE, Texas — The ACU Wildcats are set to participate in the 2026 College Baseball Series in Cleburne. The four-team ...
Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...
Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...
The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results